Tachycardia-Induced Change of Atrial Refractory Period in Humans
- 16 June 1998
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 97 (23) , 2331-2337
- https://doi.org/10.1161/01.cir.97.23.2331
Abstract
Background —Atrial fibrillation (AF) has been shown to shorten the atrial effective refractory period (ERP) and make the atrium more vulnerable to AF. This study investigated the effect of atrial rate and antiarrhythmic drugs on ERP shortening induced by tachycardia. Methods and Results —Seventy adult patients without structural heart disease were included. For the first part of the study, right atrial ERP was measured with a drive cycle length of 500 ms before and after 10 minutes of rapid atrial pacing using five pacing cycle lengths (450, 400, 350, 300, and 250 ms) in 10 patients. For the second part of the study, the remaining 60 patients were included to study the effects of antiarrhythmic drugs on changes in atrial ERP induced by AF. Atrial ERP was measured with a drive cycle of 500 ms before and after an episode of pacing-induced AF. After the patients were randomized to receive one of six antiarrhythmic drugs (procainamide, propafenone, propranolol, dl -sotalol, amiodarone, and verapamil), atrial ERP was measured before and after another episode of pacing-induced AF. In the first part of the study, atrial ERP shortened significantly after 10 minutes of rapid atrial pacing, and the degree of shortening was correlated with pacing cycle length. The second part of the study showed that atrial ERP shortened after conversion of AF (172±15 versus 202±14 ms, P P Conclusions —The atrial ERP shortening induced by tachycardia was a rate-dependent response. Verapamil, but not other antiarrhythmic drugs, could markedly attenuate this effect. However, verapamil and the other drugs could decrease the incidence and duration of secondary AF.Keywords
This publication has 27 references indexed in Scilit:
- Effect of Atrial Fibrillation on Atrial Refractoriness in HumansCirculation, 1996
- Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillationThe American Journal of Cardiology, 1993
- Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group.Circulation, 1989
- Cell calcium in the pathophysiology of ventricular fibrillation and in the pathogenesis of postarrhythmic contractile dysfunction.Circulation, 1989
- The Natural History of Lone Atrial FibrillationNew England Journal of Medicine, 1987
- Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapyJournal of the American College of Cardiology, 1985
- Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusionAmerican Heart Journal, 1983
- Epidemiologic Features of Chronic Atrial FibrillationNew England Journal of Medicine, 1982
- Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: Beneficial effect of an added beta adrenergic blocking agentThe American Journal of Cardiology, 1979
- FACTORS INFLUENCING PERSISTENCE OF SINUS RHYTHM AFTER DC SHOCK TREATMENT OF ATRIAL FIBRILLATIONActa Medica Scandinavica, 1971